- > R&D
- > TaNeDS Europe
Join TaNeDS Europe 2015/2016
Learn more about Daiichi Sankyo’s open competition grant programme
TaNeDS programme provides close partnership between you and scientists in Daiichi Sankyo to tackle unmet medical needs.
The size of grant is either around €80,000 or €150,000/year for two years.
The programme is open to principal investigators affiliated with research institution in academia and small biotech located in Europe.
The Deadline of Submission is January 15, 2016.
TaNeDS Europe Video
Part1: Brief Introduction of Daiichi Sankyo and TaNeDS Europe
Part I video describes general introduction about DaiichiSankyo and concept of TaNeDS Europe
This video explains our research interests in Cardiovascular-Metabolics section.
This video explains our research interests in Oncology section.
This video explains our research interests in Frontier section.
This video explains our research interests in Technology section.
Who we are
Daiichi Sankyo Co., Ltd. is a proprietary pharmaceutical company with origins in Japan and with over 100 years of history in drug discovery and development. Our R&D innovation and successes include a member of the statin class Pravachol® (licensed to Bristol-Myers Squibb) and the new Quinolone class Tavanic® (licensed to Sanofi Aventis). Recent drugs include the angiotensin receptor blocker Olmetec®, the ADP receptor inhibitor Efient® (co-promoted with Eli Lilly), and the FXa inhibitor LIXIANA®.
Our worldwide research and development network connects Japan, the United States, Europe, India and East Asian countries. In Europe, Daiichi Sankyo Development in London oversees clinical trials. Regarding research, U3 Pharma GmbH in Martinsried in Germany conducts research for a range of antibody drugs and the Tissue and Cell Research Centre Munich performs pharmacokinetic studies and toxicity tests.
What is TaNeDS?
To help realize our corporate philosophy – “Passion for Innovation. Compassion for Patients.” – the Daiichi Sankyo TaNeDS (Take a New Challenge for Drug diScovery) Europe serves as an interactive platform that gathers and nurtures the wisdom of researchers from diverse scientific backgrounds.
Initially launched in Japan in 2011 and in Europe in 2013, the goal of this programme is to generate breakthrough pharmaceutical drugs for human health by promoting new drug discovery themes, R&D technologies and continuous collaboration with external researchers and research groups. Each year, TaNeDS Japan (~ €70,000 for one year) has selected about 20 projects among 250 proposals.
For TaNeDS Europe (up to €150,000/year plus overhead for two years), we received about 50 proposals both in 2013 and 2014 campaign and selected two projects in each cycle. Three of them are oncology related field and one is for Structure-based Drug Design technology. This year, we expect to choose more projects than the last two years.
For the 2015/2016 application cycle, the Daiichi Sankyo TaNeDS Europe will accept applications from qualified candidates in all EU countries, Iceland, Norway and Switzerland. Research programmes of interest range from novel ideas for therapeutic target discovery and validation (initial phase of research) to compounds/biologics for treatment of diseases (practical use). This year, we start to set two sizes of the grant, up to €80,000/year and up to €150,000/year.
One key goal of TaNeDS is to foster close collaborative relationships between principal investigators of the funded projects and scientists at Daiichi Sankyo and U3 Pharma, a subsidiary company of the Daiichi Sankyo Group located in Munich. Collaboration beyond the initial funding period is also possible for successful projects to fulfil our ultimate goal of drug development.
For more information, please see our Eligibility, Funding Size and Other Information.
- About U3 Pharma
U3 Pharma GmbH, based in Martinsried near Munich, Germany, is a leader in targeted cancer drug development. Founded in July 2001 by Professor Dr. Axel Ullrich, the company has produced a pipeline of novel targeted therapeutics based on the ground-breaking discoveries made by Dr. Ullrich. Since May 2008, U3 Pharma has been an affiliate of the Daiichi Sankyo Group. As part of this global organization, U3 Pharma is striving to provide patients around the world with innovative antibody-based therapeutics.
For more information, please visit www.u3pharma.com
- About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to its strong portfolio of medicines for hypertension, dyslipidemia, bacterial infections, and thrombotic disorders, the Group’s research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics. For more information, please visit:
For our vision on R&D and the current pipeline, please visit our websites below:
For general information, please visit
About the TaNeDS Logo
A symbol of "hope to grow by partnership." Two people facing each other, holding hands expresses the intention of collaboration, to foster the seeds of hope together.